The age eligibility of Novavax’s COVID-19 vaccine will be extended.

The Ministry of Food and Drug Safety (Minister: Yu-Kyung Oh) announced that it had approved the Post Approval Change Application for the COVID-19 vaccine ‘Nuvaxovid Prefilled Syringe,’ developed by Novavax and manufactured by SK Bioscience, to change the vaccination age from the previous 18 years older to 12 years or older.

Nuvaxovid in teens aged 12 to 17 years will be administered as two 0.5ml doses three weeks apart, the same as the dosage and administration approved for those aged 18 years and older.

The MFDS determined it was appropriate to extend the allowed age of administration for Nuvaxovid bas